Literature DB >> 17152739

Ergotamine vs. metoclopramide vs. their combination in acute migraine attacks.

H Hakkarainen1, H Allonen.   

Abstract

The effect of ergotamine tartrate was compared with that of the antiemetic agent metoclopramide and with those of two combinations in a double-blind trial of 24 adult female patients with migraine. The following combinations of the drugs were used in oral administration in a total of 176 acute migraine attacks: (a) Ergotamine 1 mg, (b) Metoclopramide 20 mg, (c) Ergotamine 1 mg + metoclopramide 20 mg, (d) Ergotamine 2 mg + metoclopramide 20 mg. The duration of attacks was significantly shorter on both of the combinations compared with the single drugs. The intensity of the pain was somewhat weaker and the appearance of nausea and vomiting somewhat but not significantly less during the combination treatments. In their overall opinion the patients favored the 2 mg + 20 mg combination significantly more than the others. Both ergotamine and metoclopramide are efficient in acute migraine attacks. Their combination seems to enhance the therapeutic response in some respects.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 17152739     DOI: 10.1111/j.1526-4610.1982.hed2201010.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  3 in total

Review 1.  Pharmacological Agents Affecting Emesis : A Review (Part II).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

2.  Efficacy of metoclopramide for the treatment of acute migraine.

Authors:  Chao Jiang; Ting Wang; Zheng-Guo Qiu; Bo Chen; Bang-Jiang Fang
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

3.  Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis.

Authors:  Juliana H VanderPluym; Rashmi B Halker Singh; Meritxell Urtecho; Allison S Morrow; Tarek Nayfeh; Victor D Torres Roldan; Magdoleen H Farah; Bashar Hasan; Samer Saadi; Sahrish Shah; Rami Abd-Rabu; Lubna Daraz; Larry J Prokop; Mohammad Hassan Murad; Zhen Wang
Journal:  JAMA       Date:  2021-06-15       Impact factor: 56.272

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.